Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + dexamethasone vs physician’s choice in relapsed/refractory systemic AL amyloidosis
CTR20171165Phase 3Suspended
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ixazomib in light-chain amyloidosis, sponsored by Millennium Pharmaceuticals. Started Aug 2018; status: suspended.
02
Drugs
ixazomib
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on CTR20171165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171165.